Purpose of review
To analyse the anti-inflammatory and antioxidant properties of vitamin B12 and evaluate current evidence on vitamin B12 status in the critically ill with systemic inflammation. Recent findings Data on vitamin B12 status of intensive care unit patients are scarce. Cobalamins could potentially be useful agents for inhibiting nitric oxide synthase and nitric oxide production, controlling nuclear factor-kappa B activation, and restoring optimal bacteriostasis and phagocytosis in which transcobalamins play a proven role. The antioxidant properties of vitamin B12, with a glutathione-sparing effect, are secondary to stimulation of methionine synthase activity and reaction with free oxygen or nitrogen radicals. Large parenteral doses are routinely administered for cyanide poisoning, with only mild, reversible side-effects. Current evidence suggests that high-dose parenteral vitamin B12 may prove an innovative approach to treat critically ill systemic inflammatory response syndrome patients, especially those with severe sepsis/septic shock. In this setting, vitamin B12 and transcobalamins could modulate systemic inflammation contributing to the anti-inflammatory cascade and potentially improve outcome. Summary Despite evidence from animal studies, so far there are no clinical intervention trials that have studied vitamin B12 as a pharmaconutrient strategy for critical care. Well designed animal and clinical studies are required to clarify several outstanding questions on the optimal posology, safety, and efficacy of high-dose vitamin B12 in the critically ill. nature of any disease or other clinical condition. As absorption of dietary B12 requires an intact and functioning stomach and small bowel, acute, or chronic intestinal failure can lead to deficiency. Up to 20% of patients after gastric resection can be B12 deficient but minor deficiencies could be present in 68-100% of patients [4] . Even a mild deficiency can cause tiredness, anaemia, disorientation, and may be associated with cardiovascular disease and insulin resistance.
Currently, there are different recommendations for the use of vitamin B12 for healthy adults and children, as well as for parenteral nutrition patients, but there are no specific supplementation recommendations for critically Vitamin B12 in the critically ill Manzanares and Hardy 663 
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B12 MMCM
MMCM mediates the isomerization of methylmalonyl-CoA to succinyl-CoA, which represents a metabolic branch point wherein intermediates may enter or exit the Krebs (TCA) cycle shown in simplified form. AcCoA, acetyl-coenzyme A; MMCM, methylmalonyl-CoA-mutase; NAD, nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide; TCA, tricarboxylic acid. B6, pyridoxine; B12, cobalamin; FA, folic acid; GPx, glutathione peroxidase; GR, glutathione reductase; GSH, reduced glutathione; GSSG, oxidised glutathione; MeCbl, Methylcobalamin; MET, methionine; SAM, S-adenosylmethionine; THF, tetrahydrofolate; 5-MeTHF, 5-methyltetrahydrofolate.
ill patients with systemic inflammation due to trauma, severe sepsis/septic shock, severe pancreatitis, or other critical conditions. An important function of the vitamin is to maintain GSH status and the sulphydryl groups of enzymes in the reduced state [1] . As glyceraldehyde-3phosphate dehydrogenase activity requires GSH as a coenzyme, a B12 deficiency can adversely affect carbohydrate metabolism. Methyl malonate (arising from propionic acid, threonine, and the branched chain amino acids valine and isoleucine) is converted to succinate for energy via the tricarboxylic acid cycle ( Fig. 1 ) and to methionine, which is essential for metabolism of choline and betaine in lipid metabolism (Fig. 2 ). In addition, this vitamin is able to inhibit intracellular peroxide production, and prevent cellular apoptosis [5 ] . In vitro, vitamin B12 also has the ability of regulating inflammatory cytokine production [1,5 ,6] . All these aspects lead to the conclusion that vitamin B12 may become a promising adjunctive pharmaconutrient tool for treating systemic inflammation in the critically ill.
Vitamin B12 status in the critically ill
Worldwide, vitamin B12 deficiency and depletion are common, particularly among vegetarians and the elderly, being more prevalent in poorer populations [7] . Approximately 30% of people above 60 years are thought to be deficient and over 1.8 million elderly Americans estimated to be at risk of vitamin B12 deficiency. This may be partly due to poor bioavailability, inadequate consumption of protein (red meat), and poor dentition [8] . Vitamin B12 deficiency is also common in hospitalized elderly patients [7, 9] . In a study of 1570 patients above 65 years, Tal et al. [9] identified 15% who were B12 deficient (<200 pmol/l). The causes are multifactorial but appear to be related to the prolonged use of medications such as hypoglycaemic agents and angiotensin-converting enzyme (ACE) inhibitors. These authors also reported an unusual link between mortality and high B12 levels (>350 pmol/l) in the very old (>80 years) patients which needs further investigation [9] .
Published experiences with vitamin B12 in ICU patients are scarce. So far, there are few data on the vitamin status at ICU admission and the relationship between the prevalence of vitamin deficiencies and hospital mortality in the critically ill [10 ,11 ] . These findings could, in part, be due to low diagnostic accuracy of blood tests to assess serum vitamin B12 but TCS are elevated in severe sepsis and trauma patients, and recently holo-TCS levels have been proposed as a more sensitive and useful marker for vitamin B12 status than serum levels alone [12] [13] [14] .
In 2000, Galloway et al. [15] concluded that the group B vitamins do not exhibit acute-phase response behaviour and, in particular, vitamin B12 status does not change during a major inflammatory event, if evaluated by C-reactive protein (CRP) (a marker of acute phase response) levels between 100 and 200 mg/l. However, more recently, an Australian team have demonstrated an association between vitamin B12 status and systemic inflammation in the critically ill. In a very interesting cohort study of 129 patients, Corcoran et al. [10 ] showed that vitamin B12 admission levels differed between those patients who died and those who survived (respectively, 537 vs. 401 pmol/l, P ¼ 0.042). In addition, within the first 48 h of admission, a moderate positive correlation between vitamin B12 and CRP was found (Spearman's test r ¼ 0.309, P ¼ 0 0.001) [10 ] . Subsequently, a second cohort trial from the same group, involving another heterogeneous sample of 70 ICU patients, showed similar results. This time there was a weak association between vitamin B12 and CRP on admission to the ICU (day 1: [11 ] and a significant relationship between vitamin B12 concentration and the Sequential Organ Failure Assessment (SOFA) score was found at days 2, 3, and 4 (r ¼ 0.361, P ¼ 0.04; r ¼ 0.42, P ¼ 0.02; and r ¼ 0.48, P ¼ 0.02, respectively). According to the data from these two reports, vitamin B12 status in ICU patients does appear to reflect the inflammatory response as determined by CRP during the first days of ICU stay. Moreover, vitamin B12 seems to be an indicator of organ failure evaluated by SOFA score [11 ] . In another multicentre, cohort study [16] of a heterogeneous group of long-term ICU patients, screening for iron, B12, and folate deficiency identified 13% of patients with potentially correctable abnormalities, suggesting that screening and eventual supplementation therapy should be considered in those critically ill patients expected to have an extended ICU stay [16] .
Cardiac surgery provides another example of systemic inflammatory response syndrome (SIRS) characterized by oxidative stress with free radical generation and antioxidant depletion. In a recently published Italian study, looking for nutritional markers after major cardiac surgery, Racca et al. [17 ] showed that all vitamins remained stable within normal values, with the exception of vitamin B12, which decreased significantly from 516 AE 341 on day 0 to 445 AE 212 ng/ml on day 16 after surgery, P value is equal to 0.007. However, cobalamin levels remained within the normal range in most patients [17 ] . This decrease over time in the vitamin B12 concentration may be explained by its consumption for erythropoietic purposes, suggesting that supplementation could help to improve the nutritional status after surgical insult, particularly in those patients with suboptimal dietary intake.
A prospective, observational cohort study [18] of ICU survivors with moderate-to-severe anaemia at the time of ICU discharge has evaluated the prevalence of anaemia and associated factors during the recovery from critical illness. Bateman et al. [18] found that 53% of patients persist with anaemia 6 months after ICU discharge. Nonetheless, there was no biochemical evidence of vitamin B12, iron, or folate deficiency at any time points, suggesting that vitamin B12 deficiency does not contribute to anaemia after ICU stay [19] . In another heterogeneous sample of 96 patients who stayed in the ICU for more than 3 days, von Ahsen et al. [19] also found that vitamin B12 levels were within its respective reference interval in most patients. In contrast, a Spanish study in 40 ICU patients from Abilé s et al. [20] found high prevalence of hyperhomocysteinaemia, which is harmful for the endothelium, contributing to oxidative stress. HCYS on day 7 was higher in patients who received less than the recommended intake of vitamin B12 and folic acid than in patients with higher intake (16.3 AE 3.1 vs. 9.3 AE 54 mmol/l, P < 0.05). Adequate vitamin B12 and folic acid supplementation reduced the risk of hyperhomocysteinaemia (odds ratio 0.43; 95% confidence interval 0.01-0.08) [20] .
Most recently, Ploder et al. [21] observed increased total HCYS levels in ICU patients after multiple trauma and severe sepsis. However, the elevated HCYS (which develops when a dietary supply of folate, vitamin B12, or both is inadequate) was almost exclusively observed in nonsurvivors. HCYS levels in survivors remained stable and low [21] . As methionine is synthesized from HCYS via 5MeTHF in an irreversible reaction, a deficiency of B12 can trap folate in the methyl form. Thus, elevated folate concentrations can mask haematopoeitic symptoms of B12 deficiency, suggesting that B12 supplementation could overcome or prevent this in SIRS patients.
Finally, several drugs and conditions common to ICU could also confound some of the results in these studies. Pancreatic insufficiency, alcohol abuse, oral hypoglycaemic agents such as metformin, and drugs like para-aminosalicylic acid, prescribed for inflammatory bowel disease, are known to inhibit oral B12 absorption from supplements, which occurs almost entirely in the ileum. H2-receptor antagonists and proton pump inhibitors suppress the gastric acidity required for optimum absorption of dietary B12, and ACE inhibitors have also been associated with low B12 levels in the elderly [9] (Fig. 3) .
Vitamin B12 and its regulatory effect on transcription factor nuclear factor-kappa B: potential mechanisms for the inflammatory response
In the last few years, vitamin B12 has been proposed as a protective molecule against systemic inflammation. In a groundbreaking hypothesis, Wheatley [1, 22] has described the vitamin as a 'Scarlet Pimpernel' for the resolution of inflammation. In effect, vitamin B12 could influence the magnitude of SIRS, particularly when inflammation results from infection, cancer, or autoimmune diseases. The potential mechanisms by which the author proposes vitamin B12 and its carrier proteins, the TCS, would be able to modulate the SIRS seen in severe sepsis/septic shock and major trauma are summarized below. Vitamin B12 also maintains GSH levels, and thus antioxidant status, as well as modulating the effects of nitrosylation in cell signal transduction [1, 22] . Experimental support for Wheatley's hypothesis comes from Birch et al. [5 ] who elegantly demonstrated that the antioxidant properties of vitamin B12 are secondary to stimulation of MetH activity, reaction with free oxygen and nitrogen radicals, a GSH-sparing effect, and finally induction of a stress response [5 ] . In-vitro [6] and animal studies have also shown that the thiolatocobalamins (N-acetyl-L-cysteinylcobalamin and glutathionylcobalamin), at pharmacological doses, are powerful and effective antioxidants protecting endothelial cells from the effects of HCYS.
Low levels of vitamin B12 measured in human serum and cerebrospinal fluid, with a concomitant increase in the neurotoxic tumour necrosis factor-alpha and a decrease in epidermal growth factor concentration [23, 24] , provide further support for Wheatley's hypothesis. Moreover, methyl-cobalamin is capable of suppressing interleukin-6 production [6] . It appears that vitamin B12 downregulates nuclear factor-kappa B (NF-kB) levels in rat spinal cord and liver, which, according to Veber et al. [25] , may be an important signalling molecule of vitamin B12 deficiency, as NF-kB and p65 protein levels normalized when the gastrectomized rats were supplemented with the B vitamin. Vitamin B12 could, therefore, be considered an endogenous negative regulator of NF-kB levels affecting expression of genes encoding proinflammatory cytokines, adhesion molecules, and growth factor chemokines [25] .
In a very elegant laboratory study, Weinberg et al. [26 ] have shown that corrins such as hydroxycobalamin (OH-B12), cobinamide, and dicyanocobinamide directly inhibit the isoforms of nitric oxide synthase (NOS), particularly inducible NOS and endothelial NOS, and consequently nitric oxide production [26 ] . These authors speculate that corrins/cobalamins may play a role in modulating NOS function and nitric oxide synthesis in vivo [27] . All these experimental findings are convincing evidence that vitamin B12 is capable of modulating certain cytokines, growth factors, and other substrates with both anti-inflammatory and antioxidant properties.
High-dose parenteral vitamin B12: is it a potential pharmaconutrient for intensive care?
Pernicious anaemia is characterized by vitamin B12 deficiency, and concomitantly low GSH levels. In severe sepsis/septic shock patients, GSH levels also drop rapidly and an overshoot of GSH has been observed with vitamin B12 supplementation, suggesting that vitamin B12 has a GSH-sparing effect [1, 26 ] . Vitamin B12 is capable of increasing the cytosolic bioavailability of GSH and thus can promote the synthesis of oxidized glutathione, generating the necessary hydrogen selenide (H 2 Se), required for the synthesis of selenocysteine and selenoproteins such as glutathione peroxidase [28] . These proteins ensure that B12 reaches MetH in the cytosol and MCoA in the mitochondria.
Vitamin B12 may also play a direct role in immune defence and inflammation through an apparent bacteriostatic function of TCS, which is capable of modulating the inflammatory response [1] . Given the previously described relationship between vitamin B12 and nitric oxide metabolism [18,26 ,27] and the adjuvant relationship between TCS I and TCS II, then pharmacotherapy, involving saturation of TCS by high-dose intravenous (i.v.) vitamin B12, could restore optimal bacteriostasis and phagocytosis in SIRS patients, in whom there is an overproduction of nitric oxide (Fig. 4) .
On the basis of these in-vitro, animal, and human studies, high-dose i.v. vitamin B12 could be used as a new pharmacological strategy for ICU patients with SIRS. By utilizing both its antioxidant and anti-inflammatory properties, this novel B12 therapy should be able to protect against multiple organ dysfunction [1] . Of course, questions regarding the optimal dose and starting time, days of treatment, and the best method of administration, whether alone or in combination with other parenteral micronutrients, still need to be answered.
Vitamin B12 supply for the critically ill: safety and posology
The recommended dietary allowance of vitamin B12 for adults is only 2.4 mg/day [29] , and pregnant or lactating women are advised to have a slightly higher intake of 4 mg/day. In parenteral nutrition, several multivitamin preparations containing vitamin B12 are available, and usually provide between 6 and 50 mg of vitamin B12 [30, 31] . Standard enteral nutrition formulas contain 3-6 mg per 1500 kcal/day feed [27] . However, to consider vitamin B12 as a pharmaconutrient for critically ill SIRS patients, with the aim of inhibiting nitric oxide synthesis and promoting GSH production [5 ,26 ,27] , it would be necessary to use higher doses than those currently available in products for short-term parenteral nutrition or enteral nutrition.
Vitamin B12 is relatively nontoxic in oral doses that exceed normal requirements by 10 000-fold. In an experimental rodent model, very high i.v. doses of cyanocobalamin, up to 100 mg/kg, i.v., for 26 weeks, followed a two-compartment kinetic model, demonstrating that the molecule undergoes significant extensive tissue distribution [32] . OH-B12 when injected intramuscular (i.m.) or i.v. produces higher and more prolonged levels of B12 than the same dose of cynocobalamin. With a high renal excretion rate, OH-B12 has been successfully used to treat humans with cobalamin deficiency and cyanide poisoning with little or no evidence of toxicity.
The dose of vitamin B12 currently recommended in the British National Formulary [33] for pernicious anaemia and other macrocytic anaemias without neurological dysfunction is 1000 mg of OH-B12, initially given i.m. three times each week for 2 weeks, then once every 3 months. However, in the ICU, larger antidotal doses (usually infusions of 5-15 g hydroxocobalamin) are used to treat cyanide poisoning, which has not resulted in significant adverse effects and also offers an acceptable safety profile in children and pregnant women [34, 35] . Nevertheless, these high doses are capable of producing reversible, mild arterial hypertension, hypokalaemia, and red urine as side-effects. In 14 patients, Borron et al. [34] found a 57% incidence of adverse events; among these chromaturia (n ¼ 5) and skin discolouration (n ¼ 3) were the most frequent. Hypertension is a common side-effect due to in-vivo OH-B12 inhibition of NOS and quenching of nitric oxide. In healthy volunteers, OH-B12 caused shortlived mean blood pressure increases after initiation of i.v. infusion and returned nearly to baseline by 4 h after infusion [36] . Other adverse effects from vitamin B12 supplementation include hypersensitivity reactions, congestive heart failure, pulmonary oedema, diarrhoea, and local pain at the injection site.
Current knowledge allows us to speculate that parenteral administration of 5 g or greater amounts of OH-B12 would achieve peak blood levels of over 1000 mmol with minimal side-effects (skin and urine discolouration, and mild, reversible hypertension). Nonetheless, we agree with Corcoran et al. [11 ] who suggest that future prospective randomized controlled trials to address the difference between standard supplementation and pharmacotherapy are necessary. In addition to serum or plasma levels, assessment of vitamin B12 status has included haematocrit, haemoglobin, and erythrocyte measurements, but all have analytical and diagnostic limitations [37] . Methylmalonic acid measurement appears to offer superior diagnostic predictive value [38] . Pharmacotherapy trials would, therefore, need to monitor plasma and serum concentrations of total vitamin B12, methylmalonic acid, and HCYS as effective biomarkers of changes in vitamin B12 supply and metabolism [39] . Determination of holo-TCS levels should also be investigated.
Conclusion
Current animal and clinical data suggest that high-dose parenteral vitamin B12 may be a promising approach for improving the antioxidant and anti-inflammatory status of SIRS patients, especially those with severe sepsis and septic shock. Cobalamins could potentially be useful agents for inhibiting NOS and nitric oxide production in vivo, controlling and eventually suppressing NF-kB activation, and restoring optimal bacteriostasis and phagocytosis in which TCS play a role.
Short-term vitamin B12 therapy at a posology comparable to the high-dose hydroxycobalamin currently prescribed for patients with cyanide poisoning could be safely administered. However, more well designed animal and clinical studies are first required to clarify several Vitamin B12 in the critically ill Manzanares and Hardy 667 outstanding questions on the optimal and best tolerated dose, route, and time of administration in the critically ill.
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